Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Quadrivalent Recombinant Seasonal Influenza Vaccine
BIOLOGICAL
3 trials
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
Influenza
Influenza Immunisation
Phase 1
Flublok or Fluzone With Advax-CpG55.2 or AF03
Completed
NCT03945825
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Start: 2019-06-10
End: 2020-09-18
Updated: 2025-10-14
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
Completed
NCT05945485
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Start: 2023-10-16
End: 2026-05-21
Updated: 2026-06-22
Phase 2
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
Completed
NCT03058692
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Start: 2018-04-09
End: 2019-01-14
Updated: 2020-06-18
Related Papers
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
2025-03-18
2 citations
Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
2023-03-21
13 citations